QURE

MKT CAP:$1B

uniQure N.V.

Market Cap

$1B

Healthcare·Biotechnology·🇳🇱 Netherlands·NASDAQ

Healthcare·Biotechnology·🇳🇱·NASDAQ

Stock Price

$17.45-$5.94 (-25.40%)

Apr 21, 2026

Company Details

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal...

CEO

Matthew Craig Kapusta

IPO Date

Feb 5, 2014

Website

www.uniqure.com

Key Metrics TTM

Revenue

$16M

-40.6% YoY

Net Income

-$199M

EPS (Diluted)

-$3.48

Free Cash Flow

-$178M

Revenue / Share

$0.28

Gross Margin

71.1%

Operating Margin

-1157.9%

Net Margin

-1236.0%

FCF Margin

-1105.5%

P/S

68.9x

P/E

—

Earnings Reports

Q1 2026

May 8, 2026

PENDING

FY 2025

Mar 2, 2026

$16M-40.6%EPS -$3.46

Q4 2025

Mar 2, 2026

$6M+6.6%EPS -$0.59

Q3 2025

Nov 10, 2025

$4M+61.8%EPS -$1.38

Q2 2025

Jul 29, 2025

$5M-52.7%EPS -$0.69

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$2M	-$41M	-$54M
Q2 22	$497.0K	-$335.0K	-$56M
Q3 22	$1M	$588.0K	-$60M
Q4 22	$103M	$101M	$27M
Q1 23	$5M	$3M	-$74M
Q2 23	$2M	$1M	-$65M
Q3 23	$1M	$401.0K	-$82M
Q4 23	$7M	-$2M	-$62M
Q1 24	$8M	-$741.0K	-$54M
Q2 24	$11M	$4M	-$44M
Q3 24	$2M	$1M	-$40M
Q4 24	$5M	$5M	-$46M
Q1 25	$2M	$1M	-$39M
Q2 25	$5M	$5M	-$44M
Q3 25	$4M	$3M	-$51M
Q4 25	$6M	$2M	-$52M

Valuation

Quarter	P/S	P/E
Q1 22	2.1x	3.4x
Q2 22	17.9x	—
Q3 22	18.0x	—
Q4 22	10.4x	—
Q1 23	10.1x	—
Q2 23	9.9x	—
Q3 23	9.9x	—
Q4 23	70.0x	—
Q1 24	58.3x	—
Q2 24	40.0x	—
Q3 24	38.8x	—
Q4 24	40.9x	—
Q1 25	54.9x	—
Q2 25	77.3x	—
Q3 25	70.4x	—
Q4 25	68.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$26M	-$30M
Q2 22	-$16M	-$20M
Q3 22	-$49M	-$53M
Q4 22	-$55M	-$60M
Q1 23	-$78M	-$81M
Q2 23	-$57M	-$58M
Q3 23	$39M	$37M
Q4 23	-$50M	-$52M
Q1 24	-$61M	-$63M
Q2 24	-$33M	-$33M
Q3 24	-$37M	-$45M
Q4 24	-$53M	-$53M
Q1 25	-$44M	-$44M
Q2 25	-$40M	-$40M
Q3 25	-$16M	-$16M
Q4 25	-$78M	-$77M

Capital Expenditures

Quarter	CapEx
Q1 22	$4M
Q2 22	$5M
Q3 22	$4M
Q4 22	$5M
Q1 23	$2M
Q2 23	$1M
Q3 23	$2M
Q4 23	$2M
Q1 24	$2M
Q2 24	$604.0K
Q3 24	$9M
Q4 24	$61.0K
Q1 25	$126.0K
Q2 25	$260.0K
Q3 25	$66.0K
Q4 25	$320.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+294.7%	+24.4%
Q2 22	-99.9%	-14.1%
Q3 22	-27.1%	+29.7%
Q4 22	+78.1%	+37.1%
Q1 23	+197.2%	+42.3%
Q2 23	+387.3%	+19.3%
Q3 23	-2.9%	+36.6%
Q4 23	-93.5%	-10.2%
Q1 24	+59.3%	-21.1%
Q2 24	+359.4%	-18.3%
Q3 24	+62.5%	-49.0%
Q4 24	-21.9%	-25.4%
Q1 25	-81.5%	-34.8%
Q2 25	-52.7%	-10.9%
Q3 25	+61.8%	+28.7%
Q4 25	+6.6%	+13.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$7M	383.3%
Q2 22	$8M	1572.2%
Q3 22	$8M	525.1%
Q4 22	$12M	11.6%
Q1 23	$8M	151.4%
Q2 23	$9M	367.2%
Q3 23	$11M	788.7%
Q4 23	$7M	105.3%
Q1 24	$7M	84.7%
Q2 24	$7M	61.8%
Q3 24	$3M	150.3%
Q4 24	$5M	91.0%
Q1 25	$4M	281.4%
Q2 25	$5M	96.6%
Q3 25	$4M	95.2%
Q4 25	$5M	83.7%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$45M	—	—
Q2 22	$46M	—	$12M
Q3 22	$48M	—	$13M
Q4 22	$58M	—	$18M
Q1 23	$61M	—	$18M
Q2 23	$46M	—	$21M
Q3 23	$65M	—	$18M
Q4 23	$42M	—	$17M
Q1 24	$41M	—	$14M
Q2 24	$34M	—	$16M
Q3 24	$31M	$12M	—
Q4 24	$39M	—	$9M
Q1 25	$36M	—	$11M
Q2 25	$35M	—	$14M
Q3 25	$34M	—	$19M
Q4 25	$34M	—	$19M

Revenue Segments

Quarter	Collaboration revenues	License revenues
Q1 22	$2M	—
Q2 22	$497.0K	—
Q3 22	$1M	—
Q3 24	$200.0K	$2M
Q4 24	$246.0K	$5M
Q1 25	—	$2M
Q2 25	—	$5M
Q3 25	$119.0K	$4M
Q4 25	$45.0K	$6M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$525M	$0	$525M
Q2 22	$501M	$0	$501M
Q3 22	$440M	$0	$440M
Q4 22	$228M	$125M	$353M
Q1 23	$154M	$161M	$315M
Q2 23	$514M	$115M	$629M
Q3 23	$229M	$429M	$659M
Q4 23	$241M	$377M	$618M
Q1 24	$243M	$313M	$556M
Q2 24	$288M	$237M	$524M
Q3 24	$252M	$184M	$435M
Q4 24	$159M	$209M	$368M
Q1 25	$217M	$192M	$409M
Q2 25	$254M	$123M	$377M
Q3 25	$597M	$97M	$694M
Q4 25	$80M	$542M	$623M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	47M	-0.5%	+2.5%
Q2 22	47M	+0.1%	-0.6%
Q3 22	47M	+0.2%	+1.3%
Q4 22	47M	+0.4%	+0.3%
Q1 23	47M	+1.0%	+1.8%
Q2 23	48M	+0.4%	+2.1%
Q3 23	48M	+0.3%	+2.1%
Q4 23	48M	+0.1%	+1.8%
Q1 24	48M	+1.2%	+2.0%
Q2 24	49M	+0.5%	+2.0%
Q3 24	49M	+0.2%	+2.0%
Q4 24	49M	+0.3%	+2.1%
Q1 25	53M	+8.7%	+9.8%
Q2 25	55M	+3.2%	+12.7%
Q3 25	59M	+6.8%	+20.1%
Q4 25	58M	-1.7%	+17.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$3.9K	463
Q2 22	$1.1K	463
Q3 22	$3.1K	463
Q4 22	$205.1K	501
Q1 23	$10.6K	501
Q2 23	$4.8K	501
Q3 23	$2.8K	501
Q4 23	$13.9K	480
Q1 24	$17.7K	480
Q2 24	$23.2K	480
Q3 24	$4.8K	480
Q4 24	$25.0K	209
Q1 25	$7.5K	209
Q2 25	$25.2K	209
Q3 25	$17.7K	209
Q4 25	$74	75K

Revenue / Employee